B A C K G R O U N D Description of the condition
Acute respiratory failure, and the subsequent need for respiratory support, is a frequent cause of admission of adults to an intensive care unit (ICU) (Behrendt 2000) . In such patients respiratory support is required due to hypoxaemia, ventilatory failure, or both (Shelly 1999) . This respiratory support can be provided to the patient in either an invasive or non-invasive manner. Invasive mechanical ventilation involves the insertion of an artificial airway (either an endotracheal or tracheostomy tube). Whilst regarded as a life saving treatment, this comes with multiple inherent risks to patients. These risks include the development of ventilator induced lung injury (Gattinoni 2012), ventilator associated pneumonia (Muscadere 2008) , neuro-cognitive sequelae associated with prolonged sedation (Morandi 2011; Nelson 2000) and both increased ICU and hospital length of stay (Safdar 2005) . Where possible, therefore, invasive mechanical ventilation should be avoided, however intubation and mechanical ventilation are inevitable if the patient has stopped breathing or is unable to maintain his or her airway (Nava 2009). Non-invasive respiratory support, where possible, is the preferred method of respiratory support and can be delivered via any of the following equipment:
• low flow nasal cannulae (LFNC);
• simple face mask;
• venturi mask;
• non-rebreather mask;
• non-invasive positive pressure ventilation (NIPPV); or • high flow nasal cannulae (HFNC).
The type of delivery device chosen is largely dependent on the severity and aetiology of the patient's acute respiratory failure, with each device having benefits and drawbacks which determine their usefulness in clinical practice. LFNC are used for patients requiring a small amount of respiratory support in the form of supplemental oxygen to maintain adequate oxygenation. They deliver dry oxygen at one to six litres per minute via small prongs approximately 1.5 cm in length which sit just inside the nares of the patient's nose (O'Driscoll 2008) . Although they are generally well tolerated by patients (Zevola 2001) , the delivery of higher flows of oxygen through low flow nasal cannulae is not practicable due to the drying and irritating effects of the cold dry gas on the mucosa (Lellouche 2002) . The delivery of oxygen via a face mask is necessary if the patient has higher oxygen requirements than can be achieved with LFNC. Simple face masks are used to deliver five to 10 litres per minute of oxygen. For those patients requiring more oxygen and higher flows to maintain adequate oxygenation, non-rebreather masks can be used to deliver 10 to 15 litres per minute of oxygen (O'Driscoll 2008 
How the intervention might work
HFNC deliver blended humidified air and oxygen via wide bore nasal cannulae at a prescribed fraction of inspired oxygen (FiO 2 ) at high flow rates. HFNC do not need to be removed during oral hygiene care or when the patients talk, eat or drink, resulting in less frequent interruptions to therapy. In the growing body of evidence investigating the effects of HFNC, improvements in oxygenation ( • the ability to better meet the high inspiratory flow demands seen in patients requiring respiratory support and to deliver a more accurate FiO 2 through less dilution by entrainment of room air (Dysart 2009);
• the ability to deliver optimal humidification leading to enhanced mucociliary transport (Salah 1988) and improved patient comfort (Chanques 2009).
The purpose of this review is to compare the efficacy and safety of HFNC with other methods of non-invasive respiratory support in adult patients admitted to the ICU.
Why it is important to do this review
Whilst it has been demonstrated that HFNC offer some immediate physiological benefits to patients requiring respiratory support, it has yet to be determined whether they offer any clinically important benefits and improve patient outcomes, such as preventing progression to invasive mechanical ventilation and reducing mortality. Individual studies may tend to focus on surrogate outcomes or be underpowered to detect effects on clinically important outcomes. By performing this review we will be able to extract data on important clinical outcomes and, through meta-analysis, analyse the effects of the intervention on these with greater statistical power to detect meaningful patient differences should they exist.
As HFNC gain in popularity as a treatment modality for providing respiratory support, it is important to perform this review to synthesize the existing evidence base and to provide clear conclusions regarding the efficacy and safety of HFNC. In this way, clinicians can make decisions about how this form of respiratory support can best be incorporated into the current suite of treatment options; and in whom the treatment could be used most efficaciously.
O B J E C T I V E S
We will evaluate studies which include patients 16 years and over admitted to the ICU and who require treatment with HFNC. We will assess the safety and efficacy of HFNC compared with the comparator interventions in terms of failure of treatment, mortality, adverse events, duration of respiratory support, hospital and ICU length of stay, respiratory effects, patient reported outcomes, and cost of treatment.
M E T H O D S Criteria for considering studies for this review

Types of studies
We will include all randomized, parallel and quasi-randomized studies (including crossover studies) which compare HFNC to other forms of non-invasive respiratory support for the selected outcome measures. We will include quasi-randomized trials in this review due to the current scarcity of randomized trials in this area. Due to the inability of randomized crossover studies to detect long term patient outcomes, we will only include this trial design for the secondary outcome measures of positive end expiratory pressure, oxygenation, carbon dioxide clearance, respiratory rate, work of breathing, and patient reported outcomes. We will not impose a language restriction and we will include studies written in any language. We will exclude retrospective studies and prospective cohort or observational studies as we want to focus on the highest quality evidence from randomized studies.
Types of participants
We will include studies which enrol adult patients (16 years or over) requiring respiratory support and admitted to the intensive care unit (ICU). We will exclude participants aged less than 16 years. A Cochrane review is already published assessing the effectiveness of HFNC in preterm infants (Wilkinson 2011) and at present there is a protocol in progress for a systematic review with the Cochrane Anaesthesia Group assessing HFNC effectiveness in the paediatric population (Mayfield 2012). We will also exclude patients not admitted to an ICU.
Types of interventions
We will include humidified oxygen delivered via the nasal route at a rate greater than 20 litres per minute as the experimental intervention. We will include the following forms of non-invasive respiratory support as comparison interventions:
• low flow oxygen via nasal cannulae or mask (15 litres per minute or less);
• continuous positive airway pressure (CPAP);
• bilevel positive airway pressure (BiPAP).
Types of outcome measures
The outcome measures in this review are a mix of surrogate and clinical outcomes. We recognise that while there may be a correlation between the surrogate and clinical outcomes, it is the clinical outcomes which will provide the strongest evidence regarding the safety and efficacy of HFNC. As a result, we have chosen the clinical outcome of failure of treatment as indicated by the need for NIPPV or invasive ventilation as one of our primary outcome measures.
Primary outcomes
1. Failure of treatment as indicated by the need for NIPPV or invasive ventilation (up to 28 days) 2. In hospital mortality (up to 90 days) 3. Adverse events
Secondary outcomes
1. Duration in hours of any form of respiratory support (mechanical ventilation, NIPPV, HFNC, standard oxygen).
Length of stay in days (ICU and hospital). 3. Respiratory effects as indicated by any of the following:
• degree of atelectasis on radiological examination;
• positive end-expiratory pressure measured at the pharyngeal level (cm H 2 O);
• oxygenation (PaO 2 /FiO 2 ratio, PaO 2 , SaO 2 and SpO 2 );
• carbon dioxide clearance (PaCO 2 and pCO 2 );
• respiratory rate;
• work of breathing (joules per litre).
Patient reported outcomes as indicated by any of the following:
• dyspnoea;
• comfort;
• mouth dryness;
• patient refusal to continue with treatment.
Cost comparison of treatment (in Australian dollars).
All outcomes will be assessed at the time points reported in the included studies. For patient reported outcomes, we will accept the study authors' definitions.
Search methods for identification of studies Electronic searches
We will search the following databases:
• 
Searching other resources
We will screen the reference lists of eligible trials to identify any previously unidentified studies.
Data collection and analysis
Selection of studies
We will include in the review all randomized, parallel group, and quasi-randomized controlled trials meeting the criteria. Two authors (AC and CR) will independently examine the published titles and abstracts obtained from the search strategy and screen them for suitability. A study selection form (see Appendix 2) will be completed by each author and if the study is to be excluded we will detail the reasons for exclusion. Any disagreement will be resolved by LA. If any studies for which AC, AB or JF are listed as authors are contained within the search results, CR and LA will perform the screening for suitability with AJ resolving any disagreement.
Data extraction and management
Two authors (AC and CR) will independently extract data from each study onto the data extraction form (see Appendix 3). Data extraction forms for each study will be compared. We will resolve any disagreement by discussion with LA. If data are being extracted from any studies on which AC, AB or JF are listed as authors, CR and LA will perform the data extraction with AJ resolving any disagreement.
Assessment of risk of bias in included studies
Two authors (AC and CR) will independently assess the risk of bias in each of the studies. We will resolve any disagreements by discussion with LA. We (AC) will contact trial authors if more information is required to make an assessment on risk of bias. If the risk of bias is being assessed in any studies in which AC, AB or JF are listed as authors, CR and LA will perform the assessment with AJ resolving any disagreement. We will conduct the assessment of risk of bias in included studies using the 'Risk of bias' tool as per the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), using the quality assessment form (see Appendix 4). We will assess trials as having a low risk of bias if all of the following areas are assessed as adequate. We will assess trials as having a high risk of bias if one or more of the areas are assessed as not adequate or unclear.
We will assess the risk of bias in the following domains.
Random sequence generation (selection bias)
We will assess allocation of interventions as adequate if allocation was performed in a truly unpredictable manner (for example computerized random number generator, random number table, shuffled envelope system, coin toss or roll of the die). We will assess allocation as inadequate if it is based on non-random methods (for example day of the week, alternate patients, patient characteristics such as date of birth or hospital identifier) or the method of allocation is unclear.
Allocation concealment (selection bias)
We will assess allocation concealment as adequate if study personnel and participants were unaware of the treatment allocation of the next participant (for example central or telephone randomization, sequentially-numbered sealed opaque envelopes, on-site computer accessed only after patient enrolment). Inadequate allocation concealment will include those randomization methods deemed inadequate in point 1 (for example unsealed or non-sequential envelopes, open allocation sequence) or if it is unclear what method of allocation concealment was used. 3. Blinding of outcome assessors (performance and detection bias) It is not possible to blind the participant or the clinical staff to the treatment allocation for this intervention, therefore we will limit risk of bias to the blinding of outcome assessors. We will assess blinding as adequate where outcome assessors are definitely blinded to the treatment allocation. If there is no mention of blinding, we will deem blinding as not adequate.
Where blinding of outcome assessors is not always possible (for example respiratory rate, oxygenation, carbon dioxide clearance, work of breathing) we will assess whether this would have been likely to have introduced bias. If measurement of the outcome is unlikely to have been influenced by the lack of blinding, adequate blinding will be assumed. Where the patient is the outcome assessor (that is for patient reported outcomes) we will deem the blinding adequate if there is evidence of strategies to reduce potential bias (for example a standardised questioning strategy used for all patient reported outcomes, questioning carried out by non-study staff ). 4. Incomplete outcome data, intention to treat (attrition bias) We will deem outcome data as adequate if all withdrawals, protocol deviations and losses to follow-up are reported and the incomplete data are proportionate across groups. If this is not reported, we will assess outcome data as being inadequately dealt with. 5. Selective reporting We will assess outcome reporting as adequate if all previously stated outcomes have been fully reported. We will assess outcome reporting as inadequate if: all previously stated outcomes have not been reported, if outcomes are not fully reported, or if outcomes are reported but were not previously mentioned.
Measures of treatment effect
We will perform statistical analyses using Review Manager 5 (RevMan 5.1) and R (www.r-project.org). We will express dichotomous data as risk ratio (RR), risk difference (RD) and number needed to treat (NNT). We will express continuous data as the difference between the means. We will report the 95% confidence interval (CI) for all estimates. Ordinal data (for example mouth dryness on a scale of 0 to 10) will be treated as continuous data.
To cope with any non-normally distributed data, we will use the generalised linear model framework assuming a gamma distribution.
Unit of analysis issues
For parallel trials, we will aim to only include studies where the unit of analysis is the patient. Our meta-analysis will be based on summary statistics (for example odds ratios) derived from patient level data. For crossover trials, we will include only the outcomes from the first treatment period and treat the data as per a parallel group trial. If the data in crossover trials are not reported as per patient for the first treatment period, then we will request this data from the authors.
Dealing with missing data
We will identify the number of missing data points for each study. If these are not explicit, the trial author will be contacted. The methods used to account for missing data will be assessed on a case-by-case basis.
Missing data have the potential to bias the study: by hiding unfavourable outcomes (for example a participant who did not tolerate the treatment), or by varying between treatments (for example less missing data for the control group). We will tabulate the percent of missing data for the primary and secondary outcomes by treatment for each study. We will use sensitivity analyses to check the influence of missing data. We will drop studies from a sensitivity analysis if more than 20% of the primary or secondary outcomes are missing, or if the rate of those missing in the HFNC group is half or double the rate in any other group (with a minimum rate of 5%).
Assessment of heterogeneity
Using clinical judgement, we will assess participants, interventions and outcomes for clinical heterogeneity. We will assess methodological heterogeneity during the risk of bias assessments and by visual inspection of forest plots. We will assess statistical heterogeneity using the I 2 statistic and Chi 2 test (on a scale of 0% to 100%) (Higgins 2011).
Assessment of reporting biases
If more than 10 trials are available for the meta-analysis, we will assess publication bias by visually inspecting the symmetry of the funnel plot.
Data synthesis
Sequential meta-analysis will be used for the primary outcome of treatment failure only, as that is the key variable on which the success of the treatment is judged (that is the stopping rule) and hence the variable for which we want to avoid type I errors associated with multiple testing (see 'Sequential analysis' section below). The sequential meta-analysis recommended by Higgins and Green (Higgins 2011) is a random-effects model analysis and there is no fixed-effect analogue. Higgins and Green (Higgins 2011) specifically warned against using a fixed-effect approach for sequential meta-analysis, and their simulations showed good coverage for their sequential random-effects analysis when there was no heterogeneity. Hence we will not use a fixed effect approach for the primary variable.
For the secondary outcomes, we will conduct the meta-analysis using a fixed-effect model if the studies selected for inclusion do not have significant heterogeneity. The level of heterogeneity will be classified using the I 2 statistic as: 0% to 40%, not important; 30% to 60%, moderately important; 50% to 90%, substantially important; and > 90%, considerably important (Higgins 2002). If heterogeneity is assessed as being significant, we will use a randomeffects model. We will conduct analyses for secondary outcomes using Review Manager 5 (RevMan 5.1).
Sequential analysis
As this an emerging field there is a potential for much new evidence in the coming years, which means we may update the meta-analysis often. Repeating the meta-analysis increases the chance of a type I error. To overcome this issue we will use the approximate semiBayes approach (Higgins 2011a). This method uses monitoring boundaries, which are used to assess: i) sufficient evidence of an effect, or ii) sufficient evidence of the lack of an effect. The method is based on a pre-specified significance level, power, and a clinically important effect. We have chosen a significance level of 0.05, a power of 0.95, and a clinically important effect of log(0.4) for failure of treatment. This clinically important effect is based on the average odds ratio from three similar studies. This gives the boundaries of Z = 9.0 (upper and lower boundaries) and V max = 9.9 (vertical boundary). The Z boundary is used to assess the statistical significance for each sequential meta-analysis. The V boundary gives the maximum amount of information. So a study size beyond this V boundary with no results outside the Z boundaries means we can accept the null hypothesis. The Higgins et al (Higgins 2011a) method applies a Bayesian prior distribution to the heterogeneity. This is particularly useful when there are few trials in the meta-analysis, so that a more realistic estimate of the heterogeneity is used in the random effects model meta-analysis. We will use an inverse gamma prior for the heterogeneity (τ 2 ) with a shape parameter of 2.6 and scale parameters of 0.4. This is based on a simulation study using randomly generated groups of studies, of between two and 19 available studies, with randomly generated sample sizes between 15 and 990 per group and random treatment effects centred on a log odds ratio of 0.4. All these simulation choices were informed by similar studies in the field. We will re-visit this prior distribution before running the sequential meta-analysis to assess whether it can be updated based on the most recent evidence. We will use the R code (Higgins 2011a) to run the sequential meta-analysis. Forest and funnel plots will also be created in R using the "rmeta" package (Lumley 2009).
Subgroup analysis and investigation of heterogeneity
We will perform a subgroup analysis for the participant group and intervention if sufficient detail is present in the eligible studies.
Participants
• Age ≥ 65 years.
• Body mass index (BMI) ≥ 30 kg/m 2 .
• Aetiology of acute respiratory failure (Type 1 (hypoxia without hypercapnia) versus Type 2 (hypoxia with hypercapnia) respiratory failure).
• Acute respiratory failure versus post-extubation patients.
• Obstructive sleep apnoea.
Intervention
• HFNC flow rate:
• less than 40 litres per minute, • 40 to 50 litres per minute, • more than 50 litres per minute.
Sensitivity analysis
To determine the sensitivity of the findings to the way in which we have conducted the analysis, we will perform a sensitivity analysis in the following areas.
• Trials with unclear or low risk of bias versus high risk of bias.
• Randomized versus quasi-randomized trials.
• A random-effects model versus fixed-effect model (for secondary outcomes only).
• Excluding trials with relatively large amounts of missing data (more than 10% of data missing for each outcome variable).
Summary of findings
We will use the principles of the GRADE system (Guyatt 2008) to assess the quality of the body of evidence associated with the specific outcomes listed below.
• Failure of treatment as indicated by the need for NIPPV or invasive ventilation.
• Duration in hours of any form of respiratory support (mechanical ventilation, NIPPV, HFNC, standard oxygen).
• Length of stay in days (ICU and hospital).
• Atelectasis.
• Oxygenation.
• Carbon dioxide clearance.
• Patient reported outcomes.
We will construct a 'Summary of findings' (SoF) table using the GRADE software. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within study risk of bias (methodologic quality), the directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias.
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